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Background
The Allergic Rhinitis Clinical Investigator Collaborative
(AR-CIC) is a Canadian multi-center initiative with the
primary goal of performing standardized nasal allergen
challenge (NAC) to study the anti-allergic effects of novel
therapeutic agents for allergic rhinitis (AR). The model
further allows identification of potential mechanisms of
allergic disease and biomarkers. In this study we examined
differential counts, more specifically eosinophil numbers,
in nasal lavage samples before, 1 hour (1H) and 6 hours
(6H) after direct nasal allergen challenge.
Methods
Thirty-three atopic and five non-atopic participants were
enrolled at four study centers. All atopic participants had
AR symptoms following exposure to environmental
allergens and a supportive skin test response. Using the
Pfeiffer Bidose Nasal Delivery Device 100μl allergen
solution was delivered to each nostril. Atopic pilot study
participants were challenged with a threshold dose of
allergen determined via titration 1 week prior to NAC,
non-atopic participants were challenged with a 1:2 allergen
dose. The allergens used included either ragweed, grass,
D. farina, D. pteronyssinus and cat hair. Nasal lavage
samples were collected at baseline, 1H and 6H post NAC.
Total cell counts (TCC) were determined on unstained
samples prior to cytospin. Cytospin slides were prepared
and differentially stained (i.e. DiffQuick).
Results
Atopic individuals exhibited eosinophilia at 1H and
6H post NAC when compared to baseline samples. Non-
atopic participants did not display a significant increase in
eosinophils at any time point. Furthermore, TCCs were
increased at 1H post NAC in atopic participants. This
trend was not observed in non-atopic samples.
Conclusions
Differences were noted in eosinophil numbers (elevated)
between baseline, 1H and 6H post direct NAC only in
participants with AR. Nasal lavage collection for differen-
tial count analysis is a robust assay that can be integrated
into clinical trials conducted using the AR-CIC.
Authors’ details
1Departments of Medicine and Biomedical & Molecular Science, Queen’s
University, Kingston, ON, K7L 3N6, Canada. 2Allergy Research Unit, Kingston
General Hospital, Kingston, ON, K7L 2V7, Canada. 3Institut Universitaire de
Cardiologie et de Pneumologie de Quebec, Quebec City, QC, G1V 4G5,
Canada. 4Firestone Institute for Respiratory Health, McMaster University,
Hamilton, ON, L8N 4A6, Canada. 5Department of Medicine, McMaster
University, Hamilton, ON, L8N 3Z5, Canada. 6Pulmonary Research Group,
University of Alberta, Edmonton, AB, Canada.
Published: 3 March 2014
doi:10.1186/1710-1492-10-S1-A58
Cite this article as: Thiele et al.: The Allergic Rhinitis Clinical
Investigator Collaborative – nasal allergen induced eosinophilia.
Allergy, Asthma & Clinical Immunology 2014 10(Suppl 1):A58.
* Correspondence: jenny.thiele@queensu.ca
1Departments of Medicine and Biomedical & Molecular Science, Queen’s
University, Kingston, ON, K7L 3N6, Canada
Full list of author information is available at the end of the article
Thiele et al. Allergy, Asthma & Clinical Immunology 2014, 10(Suppl 1):A58
http://www.aacijournal.com/content/10/S1/A58 ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
© 2014 Thiele et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
